CML drug combo aims for Treatment-Free remission, but trial stalls

NCT ID NCT05413915

Terminated Disease control Sponsor: Sarit Assouline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tested whether adding asciminib to the standard drug imatinib could help people with chronic myeloid leukemia (CML) achieve a deep remission and safely stop all medication. Only 8 patients were enrolled before the study was terminated early, making it too small to draw firm conclusions. The goal was to see if the combination could lead to longer periods without relapse after stopping treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: asciminib and imatinib
What this could lead to: If successful, this approach could help some CML patients safely stop taking daily medication while keeping the leukemia under control.
What could go wrong: The trial was terminated early with only 8 participants, so results are very limited. It is unclear if adding asciminib is better than imatinib alone, and there may be side effects from combining two drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOID LEUKEMIA CHRONIC MYELOID LEUKEMIA IN REMISSION CHRONIC MYELOID LEUKEMIA, BCR/ABL-POSITIVE

Contacts and locations

Locations

Clinical Research Unit - Jewish General Hospital

Montreal, Quebec, H3T1E2, Canada
Hôpital Enfant-Jésus - CHUQ

Québec, Quebec, G1J 1Z4, Canada
Hôpital Fleurimont - CHUS (CIUSSS Estrie)

Sherbrooke, Quebec, J1H 5N4, Canada
Hôpital Maisonneuve-Rosemont (CIUSSS EMTL)

Montreal, Quebec, H1T 2M4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.